Activity of batracylin (NSC-320846) against solid tumors of mice Patricia Mucci-LoRussoLisa PolinThomas H. Corbettv Preclinical Studies Pages: 295 - 306
Reduced variation in the clonogenic assay obtained by standardization of the cell culture conditions prior to drug testing on human small cell lung cancer cell lines Peter Buhl JensenHenrik RoedHeine Høi Hansen OriginalPaper Pages: 307 - 315
Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study Eric K. RowinskyLouise B. GrochowRoss C. Donehower Preclinical Studies Pages: 317 - 325
Phase II trial of ICRF-187 in patients with acquired immune deficiency related Kaposi's Sarcoma (AIDS-KS) A. ChachouaM. GreenF. Muggia Clinical Studies Pages: 327 - 331
Phase II study of esorubicin (4′-deozydoxorubicin) in advanced epithelial carcinoma of the ovary: A Gynecologic Oncology Group study William P. McGuireJohn A. BlessingMichael L. Berman Clinical Studies Pages: 333 - 336
A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent adenocarcinoma and adenosquamous carcinoma of the cervix Robert E. SlaytonJohn A. BlessingHarrison Ball Clinical Studies Pages: 337 - 340
Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix Gregory P. SuttonJohn A. BlessingTimothy DeEulis Clinical Studies Pages: 341 - 343